Tucidinostat

Drug Profile

Tucidinostat

Alternative Names: Chidamide; CS-055; Epidaza; HBI-8000

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Chipscreen Biosciences
  • Developer Chipscreen Biosciences; Guangxi Center for Disease Control and Prevention; HUYA Bioscience International; Quintiles; Zhejiang University
  • Class Aminopyridines; Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; CD244 antigen modulators; CD8 positive T lymphocyte stimulants; Histone deacetylase inhibitors; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase III Breast cancer
  • Phase II/III Cutaneous T cell lymphoma; HIV infections
  • Phase II Adult T-cell leukaemia-lymphoma; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Dec 2016 Pharmacokinetics and adverse event data from a phase I trial in Non-Hodgkin's lymphoma (Late-stage disease) in presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (Ash-2016)
  • 01 Nov 2016 Phase-II clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater) in Japan (PO) (NCT02953652)
  • 01 Nov 2016 Phase-II clinical trials in Adult T-cell leukaemia-lymphoma (Second-line therapy or greater, In adults, In the elderly) in Japan (PO) (NCT02955589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top